A PHASE-I STUDY OF WEEKLY CISPLATIN AND WHOLE ABDOMINAL RADIATION FORTHE TREATMENT OF STAGE-III AND STAGE-IV ENDOMETRIAL CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY
Sa. Reisinger et al., A PHASE-I STUDY OF WEEKLY CISPLATIN AND WHOLE ABDOMINAL RADIATION FORTHE TREATMENT OF STAGE-III AND STAGE-IV ENDOMETRIAL CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY, Gynecologic oncology, 63(3), 1996, pp. 299-303
A Gynecologic Oncology Group Phase I study was designed to evaluate th
e toxicity of whole abdominal radiation therapy with concurrent weekly
cisplatin in patients with surgical International Federation of Gynae
cology and Obstetrics (FIGO) Stage III and IV endometrial carcinoma, C
isplatin 15 mg/m(2) was given once weekly during radiation therapy to
the whole abdomen with a pelvic boost and optional para-aortic radiati
on, All eight patients received the prescribed dose of radiation thera
py, Cisplatin chemotherapy was halted in one patient due to increased
serum creatinine after three cycles. Acute adverse effects were within
acceptable limits, with one patient admitted to the hospital after co
mpletion of treatment for diarrhea, Hematopoietic toxicity was clinica
lly unimportant. Serious late toxicities included one radiation enteri
tis requiring a bowel resection and chylous ascites in one patient, Th
ere was no late renal damage reported, This regimen appears to be tole
rated acutely and the late toxicities were similar to those seen with
whole abdominal radiation therapy alone. (C) 1996 Academic Press, Inc.